Journal of Hematology & Oncology (Apr 2023)

PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation

  • Andrea Marranci,
  • Antonella Prantera,
  • Simona Masotti,
  • Raffaella De Paolo,
  • Caterina Baldanzi,
  • Maurizio S. Podda,
  • Serena Mero,
  • Marianna Vitiello,
  • Cinzia Franchin,
  • Mariavittoria Laezza,
  • Laura Comelli,
  • Giorgio Arrigoni,
  • Tiziana Cervelli,
  • Giovanna Del Pozzo,
  • Laura Poliseno

DOI
https://doi.org/10.1186/s13045-023-01428-2
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 7

Abstract

Read online

Abstract In human cells BRAF oncogene is invariably expressed as a mix of two coding transcripts: BRAF-ref and BRAF-X1. These two mRNA isoforms, remarkably different in the sequence and length of their 3′UTRs, are potentially involved in distinct post-transcriptional regulatory circuits. Herein, we identify PARP1 among the mRNA Binding Proteins that specifically target the X1 3′UTR in melanoma cells. Mechanistically, PARP1 Zinc Finger domain down-regulates BRAF expression at the translational level. As a consequence, it exerts a negative impact on MAPK pathway, and sensitizes melanoma cells to BRAF and MEK inhibitors, both in vitro and in vivo. In summary, our study unveils PARP1 as a negative regulator of the highly oncogenic MAPK pathway in melanoma, through the modulation of BRAF-X1 expression.

Keywords